Astellas Pharma Inc
Astellas Pharma Inc. manufactures, markets, imports, and exports pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric cancer; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also provides VEOZAH, a treatment for vasomotor symptoms due to m… Read more
Astellas Pharma Inc (ALPMF) - Total Assets
Latest total assets as of December 2025: $3.61 Trillion USD
Based on the latest financial reports, Astellas Pharma Inc (ALPMF) holds total assets worth $3.61 Trillion USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Astellas Pharma Inc - Total Assets Trend (2004–2025)
This chart illustrates how Astellas Pharma Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Astellas Pharma Inc - Asset Composition Analysis
Current Asset Composition (March 2025)
Astellas Pharma Inc's total assets of $3.61 Trillion consist of 36.0% current assets and 64.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.6% |
| Accounts Receivable | $632.52 Billion | 18.9% |
| Inventory | $297.26 Billion | 8.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.12 Trillion | 33.7% |
| Goodwill | $415.21 Billion | 12.4% |
Asset Composition Trend (2004–2025)
This chart illustrates how Astellas Pharma Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Astellas Pharma Inc's current assets represent 36.0% of total assets in 2025, a decrease from 64.2% in 2004.
- Cash Position: Cash and equivalents constituted 5.6% of total assets in 2025, down from 38.3% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 45.0% of total assets, an increase from 3.0% in 2004.
- Asset Diversification: The largest asset category is intangible assets at 33.7% of total assets.
Astellas Pharma Inc Competitors by Total Assets
Key competitors of Astellas Pharma Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
PINK:NVSEF
|
USA | $115.49 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
AbbVie Inc
NYSE:ABBV
|
USA | $133.96 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
Zhejiang Zhenyuan Share Co Ltd
SHE:000705
|
China | CN¥3.03 Billion |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
China | CN¥877.99 Million |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.58 Billion |
Astellas Pharma Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Astellas Pharma Inc generates 0.57x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Astellas Pharma Inc generates $ 1.52 in net profit.
Astellas Pharma Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.09 | 1.04 | 1.47 |
| Quick Ratio | 0.84 | 0.80 | 1.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $116.79 Billion | $ 51.36 Billion | $ 280.22 Billion |
Astellas Pharma Inc - Advanced Valuation Insights
This section examines the relationship between Astellas Pharma Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.71 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -6.4% |
| Total Assets | $3.34 Trillion |
| Market Capitalization | $16.93 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Astellas Pharma Inc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Astellas Pharma Inc's assets decreased by 6.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Astellas Pharma Inc (2004–2025)
The table below shows the annual total assets of Astellas Pharma Inc from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | $3.34 Trillion | -6.44% |
| 2024-03-31 | $3.57 Trillion | +45.31% |
| 2023-03-31 | $2.46 Trillion | +5.32% |
| 2022-03-31 | $2.33 Trillion | +2.58% |
| 2021-03-31 | $2.27 Trillion | -1.92% |
| 2020-03-31 | $2.32 Trillion | +22.16% |
| 2019-03-31 | $1.90 Trillion | +2.12% |
| 2018-03-31 | $1.86 Trillion | +2.05% |
| 2017-03-31 | $1.82 Trillion | +1.20% |
| 2016-03-31 | $1.80 Trillion | +0.32% |
| 2015-03-31 | $1.79 Trillion | +8.50% |
| 2014-03-31 | $1.65 Trillion | +14.36% |
| 2013-03-31 | $1.45 Trillion | +3.21% |
| 2012-03-31 | $1.40 Trillion | +4.91% |
| 2011-03-31 | $1.34 Trillion | -2.13% |
| 2010-03-31 | $1.36 Trillion | +1.17% |
| 2009-03-31 | $1.35 Trillion | -6.30% |
| 2008-03-31 | $1.44 Trillion | -2.15% |
| 2007-03-31 | $1.47 Trillion | -7.18% |
| 2006-03-31 | $1.58 Trillion | +73.44% |
| 2005-03-31 | $913.56 Billion | +1.20% |
| 2004-03-31 | $902.70 Billion | -- |